Barry M Brenner - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Barry M Brenner

Showing results (41-50 of 70) with videos related to

Pageof 7

Sort By:

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 19, 2009

Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populationsBjörn Oqvist, Barry M Brenner, João Paulo Oliveira, et al.

Journal of the American Society of Nephrology : JASN|September 20, 2001

Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition aloneMaarten W Taal, Vesselin D Nenov, Waichi Wong, et al.

Journal of the American Society of Nephrology : JASN|December 8, 2004

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial resultsGiuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, et al.

Pharmacoeconomics|June 10, 2006

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides, Shahnaz Shahinfar, Erik J Dasbach, et al.

Journal of the American College of Cardiology|July 11, 2009

Dual renin-angiotensin system blockade and kidney diseaseHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.

Circulation|August 11, 2004

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyDick de Zeeuw, Giuseppe Remuzzi, Hans-Henrik Parving, et al.

Kidney International|May 20, 2004

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAALDick de Zeeuw, Giuseppe Remuzzi, Hans-Henrik Parving, et al.

Diabetes Care|March 1, 2003

Losartan reduces the costs associated with diabetic end-stage renal disease: the RENAAL study economic evaluationWilliam H Herman, Shahnaz Shahinfar, George W Carides, et al.

Journal of the American Society of Nephrology : JASN|May 6, 2005

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) studyZhongxin Zhang, Shahnaz Shahinfar, William F Keane, et al.

Journal of the American Society of Nephrology : JASN|January 18, 2008

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathyHans-Henrik Parving, Dick de Zeeuw, Mark E Cooper, et al.

Pageof 7

Search research articles

Showing results (41-50 of 70) with videos related to

Sort By:

Pageof 7

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 19, 2009

Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populationsBjörn Oqvist, Barry M Brenner, João Paulo Oliveira, et al.

Journal of the American Society of Nephrology : JASN|September 20, 2001

Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition aloneMaarten W Taal, Vesselin D Nenov, Waichi Wong, et al.

Journal of the American Society of Nephrology : JASN|December 8, 2004

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial resultsGiuseppe Remuzzi, Piero Ruggenenti, Annalisa Perna, et al.

Pharmacoeconomics|June 10, 2006

The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathyGeorge W Carides, Shahnaz Shahinfar, Erik J Dasbach, et al.

Journal of the American College of Cardiology|July 11, 2009

Dual renin-angiotensin system blockade and kidney diseaseHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.

Circulation|August 11, 2004

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathyDick de Zeeuw, Giuseppe Remuzzi, Hans-Henrik Parving, et al.

Kidney International|May 20, 2004